All In Biotech

Drug Trial Radar · NCT04015518

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIb Dose-finding Study to Evaluate Safety and Efficacy of Different Subcutaneous Doses of BI 655130 in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP)

Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

152

Actual

Start

Jul 31, 2019

Primary completion

Aug 6, 2020

Study completion Jul 28, 2021

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16. The target dose(s) will be estimated from the model by incorporating information on the minimum clinically relevant effect and accounting for safety. Supportive dose-ranging assessments will also be done on pre-specified secondary endpoints.

Conditions

  • Palmoplantar Pustulosis (PPP)

Interventions

  • SpesolimabDrug

    Subcutaneous injections of Spesolimab starting at week 16, for a total treatment time until week 52.

  • PlaceboDrug

    Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.

  • SpesolimabDrug

    Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.

  • SpesolimabDrug

    Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.

  • SpesolimabDrug

    Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.

  • SpesolimabDrug

    Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From BaselineTime frame: week 0 (baseline) and week 16

Locations

88 sites in 15 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center, PC

    Birmingham, Alabama

  • Wallace Medical Group

    Beverly Hills, California

  • Therapeutics Clinical Research

    San Diego, California

  • Advanced Medical Research PC

    Sandy Springs, Georgia

  • Epiphany Dermatology of Kansas, LLC

    Overland Park, Kansas

  • University of Missouri Health System

    Columbia, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Skin Specialists, P.C.

    Omaha, Nebraska

  • The Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

  • Paddington Testing Co., Inc.

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Menter Dermatology Research Institute

    Dallas, Texas

  • University of Utah Health

    Murray, Utah

  • Virginia Clinical Research, Inc.

    Norfolk, Virginia

  • Paratus Clinical Research Woden

    Phillip, Australian Capital Territory, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Veracity Clinical Research

    Wooloongabba, Queensland, Australia

  • Skin Health Institute Inc

    Carlton, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Brussels - UNIV Saint-Luc

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CARe Clinic

    Red Deer, Alberta, Canada

  • Dr. Irina Turchin PC Inc.

    Fredericton, New Brunswick, Canada

  • SimcoDerm Medical and Surgical Dermatology Centre

    Barrie, Ontario, Canada

  • The Guenther Dermatology Research Centre

    London, Ontario, Canada

  • York Dermatology Clinic and Research Centre

    Richmond Hill, Ontario, Canada

  • K. Papp Clinical Research Inc.

    Waterloo, Ontario, Canada

  • Innovaderm Research Inc.

    Montreal, Quebec, Canada

  • CCBR Czech a.s.

    Pardubice, Czechia

  • Sanatorium Prof. Arenebergera

    Prague, Czechia

  • CCBR Czech Prague s.r.o.

    Prague, Czechia

  • HOP l'Archet

    Nice, France

  • HOP Saint-Louis

    Paris, France

  • HOP Larrey

    Toulouse, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Germany

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Universitätsklinikum Schleswig-Holstein, Campus Kiel

    Kiel, Germany

  • CRU Hungary Ltd, Private Practice, Miskolc

    Miskolc, Hungary

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.